BRIEF-Celldex Reports Results From Phase 2 Study Of Barzolvolimab In Prurigo Nodularis

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

CLDX

0.00

July 21 (Reuters) - Celldex Therapeutics Inc CLDX.O:

  • CELLDEX REPORTS RESULTS FROM PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS

  • CELLDEX THERAPEUTICS - PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS DID NOT MEET KEY EFFICACY OBJECTIVES

  • CELLDEX THERAPEUTICS - PHASE 3 CSU TOPLINE DATA EXPECTED SEPT/OCT 2026; PHASE 3 SD AND COLDU ENROLLMENT ON TRACK

  • CELLDEX THERAPEUTICS - DISCONTINUES PHASE 2 STUDY OF BARZOLVOLIMAB IN PRURIGO NODULARIS

  • CELLDEX THERAPEUTICS INC: FAVORABLE SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES, INCLUDING WITH NEW 450MG LOADING DOSE AND UP TO 300MGQ4W REGIMEN

  • CELLDEX THERAPEUTICS - PROFOUND SYSTEMIC MAST CELL DEPLETION OBSERVED IN PHASE 2 STUDY

  • CELLDEX THERAPEUTICS: BARZOLVOLIMAB WELL TOLERATED; LOADING DOSE FOLLOWED BY Q4W DOSING SHOW FAVORABLE SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES

Source text: ID:nGNX2lQxg8

Further company coverage: CLDX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.